Current and emerging lupus treatments.
New developments in the treatment of lupus have been lacking until recently. It is hoped that new immunomodulating therapies, including a synthetic form of dehydroepiandrosterone (prasterone), will help reduce the need for steroid treatment among patients with mild-to-moderate disease, thereby reducing the morbidity and cost associated with steroid-related side effects. In addition, newer treatments for more severe systemic lupus erythematosus appear to be on the horizon, the most promising of which include biologic agents. Meanwhile, several improvements have been made to traditional therapies that may also benefit patients.
Wallace
D
D
D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D000962:Antimalarials / Q000627:therapeutic use; D003687:Dehydroepiandrosterone / Q000627:therapeutic use; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007555:Isoxazoles / Q000627:therapeutic use; D000077339:Leflunomide; D008180:Lupus Erythematosus, Systemic / Q000188:drug therapy*; D009173:Mycophenolic Acid / Q000031:analogs & derivatives* / Q000627:therapeutic use; D009841:Oligonucleotides / Q000627:therapeutic use
D000305:Adrenal Cortex Hormones; D000894:Anti-Inflammatory Agents, Non-Steroidal; D000962:Antimalarials; D007166:Immunosuppressive Agents; D007555:Isoxazoles; D009841:Oligonucleotides; D003687:Dehydroepiandrosterone; D000077339:Leflunomide; D009173:Mycophenolic Acid; C094104:abetimus